Study Information for Patients Investigating a potential new treatment for Dry Eyes
Quick Reference:
What is the purpose of this study?
Where is my nearest study site?
What is the purpose of this study?
This study aims to evaluate the safety and efficacy of a potential new eye drop treatment in people with dry eyes compared to a version of the study medication that has no active ingredient (we call this the “vehicle”). The potential new treatment has been designed to repair eye tissue damage caused by dry eyes, thus treating the associated symptoms faster and more effectively.
Where is my nearest study site?
We are currently recruiting for this study in the following locations:
- St. Andrew's Hospital - Adelaide, SA
What are dry eyes?
Dry eye is a common condition that results from inadequate tear production or poor tear quality, causing eye discomfort and inflammation. Ageing, hormonal changes, and prolonged screen use are common contributors, leading to symptoms such as eye redness, blurry vision, and a burning sensation in the eyes.
Who can participate?
To take part in this study, you will need to meet all the following:
- At least 18 years of age.
- Have a reported history of dry eyes for at least 6 months.
- Have a history of use or desire to use eye drops for dry eyes for at least 6 months.
Who cannot participate?
Unfortunately, if any of the following apply to you, this study is not the right fit for you:
- Have had any recent surgeries related to the eyes (these will be discussed during phone screening).
- Anticipate using any contact lenses during the study
- Are pregnant, breastfeeding, or planning to become pregnant during the study.
Please note, additional eligibility criteria apply and will be discussed in a phone call with our team.
What is involved?
If you are deemed eligible for the study, your participation is expected to last approximately 7 weeks, with up to 8 visits at the study site. Initially, you'll confirm eligibility and begin using vehicle eye drops for 7 days. Qualified participants will then be randomly assigned to continue with the vehicle or switch to the active solution. Treatment involves self-administration twice daily for 42 days, alongside symptom tracking and clinic visits on six more occasions.
Participation in this research is voluntary, and you may withdraw from the study at any time.
If you take part in the research study, there will be:
- Remuneration: Be remunerated to volunteer your time.
- Free study-related medical care: Be among the first to access potential new research treatments before they are widely available
- Expert eye monitoring: Receive top-tier eye care and monitoring from experienced healthcare professionals.
Why is this study important?
This study is important because dry eye has become more common in Australia since the onset of COVID-19, which has been linked to increased screen time and subsequent eye strain. Dry eye can negatively impact a person’s sleep quality, professional performance, and overall well-being. The findings from this study could pave the way for improved relief from the symptoms of dry eye.
Who is involved?
This study is being sponsored by Stuart Therapeutics; a pharmaceutical company founded in 2018. Stuart Therapeutics is dedicated to developing innovative treatments for a variety of chronic eye diseases, including dry eyes, glaucoma, and myopia (shortsightedness), and making a meaningful difference in the lives of those affected by these conditions.
Your participation in this research study has the potential to advance our understanding of medical science, lead to improved treatments, and deliver better health outcomes.
FOR MORE INFORMATION AND TO REGISTER YOUR INTEREST, VISIT US AT DRYEYESTUDY.COM.AU
This trial has been approved by an independent ethics committee.
Ready to register? Click here to sign up/login to Evrilink and start your clinical trial journey.
Still have questions? Use the form below and one of our patient experience team members will be in touch to assist with your enquiry!